Objective: Sildenafil is occasionally used as rescue treatment for preterm infants with severe bronchopulmonary dysplasia and pulmonary arterial hypertension. In adults, sildenafil treatment has been associated with several ophthalmological adverse effects, including nonarteritic ischaemic optic neuropathy. We reviewed the effect of sildenafil on retinopathy of prematurity (ROP) in very preterm infants.
Introduction
Sildenafil, a highly selective phosphodiesterase type 5 inhibitor has been commonly used for the treatment of erectile dysfunction and pulmonary arterial hypertension (PAH) in adults. It decreases pulmonary arterial pressure by inhibiting phosphodiesterase type 5, an enzyme that is abundant in lung vasculature in patients with PAH, thereby delaying the degradation of cyclic guanosine monophosphate, resulting in a reduction in pulmonary vascular resistance. 1 Sildenafil has been shown in adults with PAH to improve exercise capacity and functional status. [2] [3] [4] In recent years, children with PAH have been treated with sildenafil although data from controlled trials are still scarce. These trials showed that oral sildenafil is well-tolerated and has the potential to improve exercise capacity in children with PAH. 5, 6 Sildenafil has been used in neonates as a rescue treatment for preterm infants with severe bronchopulmonary dysplasia (BPD) and PAH, and in newborns with persistent pulmonary hypertension of the newborn where nitric oxide was not available. [7] [8] [9] In adults, the most common ophthalmological adverse effects of sildenafil use include mild and transient blurred vision, cyanopsia and altered perception of light. 10, 11 Postmarketing surveillance of sildenafil has detected a number of case reports, reporting nonarteritic ischaemic optic neuropathy, associated with the use of sildenafil in adults. 11, 12 However a causal relationship between sildenafil and nonarteritic ischaemic optic neuropathy has not been established in a number of systemic reviews. 11, 13, 14 In newborns, one case report raised the possible association of aggressive retinopathy of prematurity (ROP) and the use of sildenafil. 15 A recent study investigated potentially adverse ocular effects of sildenafil treatment in term and preterm infants born after 34 weeks gestation. The results did not show an association between sildenafil and ophthalmological findings. 16 To the best of our knowledge, there are no other data on the effect of sildenafil on the circulation of the developing eye.
This study investigates the effect of sildenafil treatment on the progression of ROP in very preterm infants.
Methods

Setting
The study was conducted at the neonatal intensive care unit (NICU) of the Mercy Hospital for Women, a tertiary perinatal centre in Melbourne, Australia, with B6000 births annually and B200 very low birth weight infants admitted to the NICU per year. The study was approved by the Institutional Human Research Ethics Committee.
Study design and population
This is a retrospective case-control study. The study population consisted of all premature infants born before 30 weeks gestation and admitted to the NICU between May 2004 and May 2010, who were treated with sildenafil for PAH in combination with evolving or established BPD. PAH was assessed using echocardiography by measuring tricuspid regurgitation jet to calculate the estimated right ventricular systolic pressure as described by Skinner et al. 17 All echocardiograms were performed by the same echocardiographer. The decision to commence sildenafil treatment was based on at least two echocardiograms showing evidence of PAH. Sildenafil was only started once the parents had been informed about the treatment plan and its potential risks by the neonatologist on duty, and only after the parents had consented to the treatment. Parents were made aware that the treatment with sildenafil was experimental in this population, and that it was considered a rescue treatment for infants with established or evolving BPD dysplasia and evidence of PAH on echocardiogram. Parental consent was documented in the infant's medical file.
A control group matched for gestation, birth weight, gender and place of birth (inborn versus outborn; outborn infants were commonly born in nontertiary hospitals) was identified from the departmental database by taking the next baby born with a gestational age ±1 week and ±10% birth weight of the index case. For every preterm infant treated with sildenafil, three matched controls were studied. Demographic data, dose and duration of sildenafil treatment, ROP examination results, respiratory data such as duration of invasive and noninvasive respiratory support, the need for corticosteroid therapy and incidence of BPD (defined as oxygen requirement or respiratory support at 36 weeks corrected gestational age), were retrieved from patient records and the departmental database. ROP status before commencing sildenafil treatment and maximum ROP status during sildenafil therapy were analysed. Any increase in ROP status during sildenafil therapy was judged as ROP progression. Control cases were analysed in a similar way, taking the start date of sildenafil therapy of their index case as baseline ROP status and the maximum increase in ROP status during the duration of the index cases' sildenafil therapy. For infants born <32 weeks gestation, the NICU's overall BPD rate during the study period was 19.6%, 5.8% were discharged home on oxygen and 1.1% required laser treatment for ROP.
ROP screening
All babies with a birth weight <1250 g and/or gestational age <30 weeks at birth have ophthalmological review. The infant's first eye examination occurs at 30 weeks corrected gestational age. Eye examinations are conducted fortnightly, however, if concern arises from an examination, the examination is repeated on a weekly basis. All eye examinations are performed by an experienced paediatric consultant ophthalmologist who is not involved in the routine clinical management of infants in the NICU. If the ophthalmologist considers ROP severe and laser treatment likely, a second paediatric consultant ophthalmologist reviews the infant before the final decision is made. ROP is characterised by stage, zone and plus disease. Stage 3 to 5 ROP is considered severe ROP.
Statistical analysis
Means and s.d. or median and interquartile range (IQR) were calculated where appropriate. The t-test for paired samples was used for continuous variables and McNemar's test was used for comparison of binary variables. The odds ratio for an increase in ROP stage was derived from conditional logistic regression methods using Stata 11.2 (StataCorp, College Station, TX, USA).
Results
Baseline characteristics and respiratory data
During the study period, 705 infants were born <30 weeks gestation. 548 Infants had ophthalmology screening while an inpatient. 86 Infants were transferred to another hospital and 71 infants died before ophthalmological screening. In all, 17 of the 548 infants were treated with sildenafil and constituted the treatment group. The control group comprised 51 infants. Sildenafil was commenced at a median of 76 days of life (IQR 67 to 91), and given for a median of 52 days (IQR 47 to 72). The median daily dose was 3 mg/kg/day (IQR 2.5 to 4.8) and the median cumulative dose was 139.6 mg/kg (IQR 97.9 to 336.9). Infants in the sildenafil group required more mechanical ventilation and noninvasive respiratory support, more corticosteroid therapy and their incidence of BPD was higher than in the control group. The baseline characteristics and respiratory data of both groups are displayed in Table 1 . 
Discussion
Sildenafil is increasingly used as a treatment option for neonates with pulmonary hypertension, including preterm infants with severe BPD and PAH. Previous studies have shown that oral sildenafil may be of benefit and well-tolerated in newborns with severe PAH. [7] [8] [9] However, there are minimal data on the effect of sildenafil on the circulation of the developing eye.
In animal studies, no retinal histopathological evidence of sildenafil toxicity was shown in rats and dogs exposed to high doses of sildenafil for 6 to 12 months. 18 However, visual abnormalities have been reported with sildenafil use, mainly in adult studies. Morales et al. 19 reported that 3% of patients treated with sildenafil described transient abnormal vision, which include blue tinge to light, and increased brightness of light. Short-term and long-term studies of the ophthalmological safety of sildenafil have produced mixed results. These studies concluded that sildenafil can cause short-term transient, reversible effects on colour discrimination in the blue-green range, but not on visual acuity, visual fields and visually evoked potentials. 18, 20 Others have postulated that nonarteritic ischaemic optic neuropathy in adults may be associated with the use of sildenafil. However, an analysis of 30 relevant references by Hatzimouratidis 11 demonstrated that no causal relationship between sildenafil and the development nonarteritic ischaemic optic neuropathy has been found. Other studies have examined the effects of sildenafil on ophthalmological blood flow in healthy individuals, using a variety of techniques and with varying results. Harris et al. 13 reviewed all published studies on the effects of sildenafil on retinal and retrobulbar haemodynamics in humans. The authors found that most studies suggested an increase in choroidal blood flow with a lesser effect on the retinal vasculature.
A case report in 2004 linked the use of sildenafil to the development of severe ROP in an infant born at 26 weeks gestation with intrauterine growth restriction and a very difficult intensive care course. 15 The authors commented that they had observed an increased incidence of ROP in their unit, coinciding with the use of sildenafil. However Pierce et al. 21 commented in their letter that the causal role of sildenafil in the development of ROP was nonconvincing. Kehat et al. 16 recently demonstrated in a retrospective observational study, including 22 term and near-term neonates born after 34 weeks gestation and treated with sildenafil during a complicated intensive care course, that ocular complications were not directly linked to sildenafil use. Our study is the first study attempting to address whether sildenafil affects the progression of ROP in very preterm infants. Infants in the sildenafil group had a more complicated clinical course requiring more invasive and noninvasive respiratory support. More infants in the sildenafil group required postnatal steroids as rescue treatment to facilitate extubation from the ventilator. Despite the more difficult intensive care course, we found no difference in the progression of ROP between the groups. The incidence of ROP in our patients was 64.7% in the sildenafil group and 70.6% in the control group, similar to the incidence of 68% among infants of <1251 g described by the Early Treatment of ROP Cooperative Group. 22 One of the theories of pathogenesis of ROP describes ROP as a biphasic disease. The first phase, which occurs from birth to B30 to 32 weeks postmenstrual age, is a hyperoxic phase that leads to retinal vessel regression and tissue hypoxia. The second phase of ROP begins around 32 to 34 weeks postmenstrual age and is characterised by hypoxia-induced retinal neovascularisation. 23 In our study, sildenafil was commenced at a median of 76 days of life, which is B36 weeks postmenstrual age, a time point where onset of ROP already occurred. Infants were treated for a median of 52 days with sildenafil, and 29 and 24% of infants in the sildenafil and control group, respectively, had a progression of ROP during the treatment. Sildenafil use did not appear to affect the progression of ROP in this cohort.
Our study has some limitations. It is a retrospective casecontrol study and owing to the nature of sildenafil therapy in neonates as a rescue treatment, the sample size is small. We tried to address this issue by choosing three matched controls per index case to allow for greater statistical accuracy. We matched the control group as close as possible to the index cases by matching for gestation, birth weight, gender and place of birth however it was not possible to match control cases for severity of BPD. Very preterm infants receiving sildenafil represent a patient group where standard respiratory management has failed, and rescue therapies such as postnatal steroids and sildenafil are under trial to improve the respiratory status. 9 
Conclusion
Sildenafil treatment did not affect ROP progression or increase the need for laser treatment in this cohort of very preterm infants. Prospective trials are required to establish a definite safety profile.
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